Investor Optimism Dampens as Walgreens Boots Alliance Struggles With Market Turbulence
Investor Optimism Dampens as Walgreens Boots Alliance Struggles With Market Turbulence
Walgreens Boots Alliance Inc. (NASDAQ:WBA) is facing tumultuous times as it grapples with a challenging turnaround, leading to a drastic decline in its stock value, marking its worst performance in over five years.
Walgreens Boots Alliance Inc.（納斯達克股票代碼：WBA）正面臨動盪時期，該公司正在努力應對艱難的轉機，導致其股票價值急劇下跌，創下五年來最差的表現。
The company's shares plummeted by 18% in April, nearing a 26-year low, following a downward revision of its outlook.
在向下修正展望後，該公司的股價在4月份暴跌了18％，接近26年低點。
This revision was accompanied by concerns over decreased consumer spending and the revelation of a substantial unpaid tax liability amounting to $2.7 billion, adding to the woes of the beleaguered drugstore chain.
此次修訂伴隨着對消費者支出減少的擔憂，以及總額爲27億美元的巨額未繳納稅款的披露，這加劇了這家陷入困境的連鎖藥店的困境。
In March, Walgreens Boots Alliance reported second-quarter fiscal year 2024 earnings and narrowed the fiscal year 2024 adjusted EPS guidance to $3.20-$3.35 versus prior guidance of $3.20-$3.50 and consensus of $3.24.
3月，沃爾格林靴子聯盟公佈了2024財年第二季度收益，並將2024財年調整後的每股收益預期縮小至3.20美元至3.35美元，而之前的預期爲3.20美元至3.50美元，共識爲3.24美元。
Over the past eight years, Bloomberg highlighted that Walgreens has witnessed consistent losses in its stock value, primarily due to its struggle with high debt stemming from an aggressive acquisition spree.
彭博社強調，在過去的八年中，沃爾格林的股票價值持續下跌，這主要是由於其難以應對激進的收購狂潮所導致的高額債務。
Despite this downturn, the company remains optimistic about its prospects, embarking on a strategic review of its operations to regain investor confidence and reignite growth.
儘管出現了這種低迷，但該公司仍對其前景持樂觀態度，開始對其運營進行戰略審查，以恢復投資者的信心並重振增長。
Key management changes, including the departure of former CEO Roz Brewer, have further unsettled investors, with the stock shedding nearly half of its value during her tenure.
包括前首席執行官羅茲·布魯爾離職在內的關鍵管理層變動進一步使投資者感到不安，該股在她任職期間貶值了近一半。
The company is now exploring potential separations, including discussions to split from its UK pharmacy chain, Boots, and assessing options for its specialty pharmacy business, Shields Health Solutions.
該公司目前正在探索潛在的分離方案，包括討論脫離其英國連鎖藥房Boots的問題，以及評估其專業藥房業務Shields Health Solutions的備選方案。
However, Wall Street's sentiment toward Walgreens remains cautious, with analysts adopting a wait-and-see approach, the Bloomberg report added.
但是，彭博社報告補充說，華爾街對沃爾格林的情緒仍然謹慎，分析師採取觀望態度。
While some anticipate positive outcomes from the strategic review, others express concerns about potential asset monetization, fearing the loss of crucial components of the business or selling assets at a discount.
儘管有些人預計戰略審查將取得積極成果，但另一些人則對潛在的資產貨幣化表示擔憂，擔心業務的關鍵組成部分會流失或以折扣價出售資產。
Amidst these challenges, the broader landscape of the pharmaceutical market also faces turbulence, with Walmart Inc (NYSE:WMT) announcing the closure of its primary-care clinics, reflecting the difficulties companies face expanding into the sector.
在這些挑戰中，製藥市場的更廣泛格局也面臨動盪，沃爾瑪公司（紐約證券交易所代碼：WMT）宣佈關閉其初級保健診所，這反映了各公司向該行業擴張所面臨的困難。
Despite the prevailing skepticism, citing some analysts, Bloomberg highlights potential avenues for Walgreens to improve its fortunes.
彭博社援引一些分析師的話說，儘管普遍持懷疑態度，但強調了沃爾格林改善其命運的潛在途徑。
Price Action: WBA shares are down 1.97% at $17.38 at the last check Wednesday.
價格走勢：在週三的最後一次檢查中，WBA股價下跌1.97％，至17.38美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：此內容部分是在人工智能工具的幫助下製作的，並由Benzinga的編輯審閱和發佈。
Photo via Wikimedia Commons
照片來自維基共享資源
譯文內容由第三人軟體翻譯。